A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult Participants
← catalyst calendarSponsored by AbbVie (industry) · ABBV — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · None · Basic science
Enrollment
59actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-08 | actual | When the study began enrolling |
| Primary completion | 2025-11-25 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-25 | actual | The whole study's end, after follow-up |
| First posted | 2025-04-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Intervention
- Drug: Risankizumab — also filed as SKYRIZI
Primary outcomes
what the primary-completion date above is the date OFMaximum Observed Plasma Concentration (Cmax) of Risankizumab
measured Up to approximately 141 days
Time to Cmax (Tmax) of Risankizumab
measured Up to approximately 141 days
Apparent Terminal Phase Elimination Rate Constant (β) of Risankizumab
measured Up to approximately 141 days
Terminal Phase Elimination Half-life (t1/2) of Risankizumab
measured Up to approximately 141 days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUCt) of Risankizumab
measured Up to approximately 141 days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCinf) of Risankizumab
measured Up to approximately 141 days
Number of Participants Experiencing Adverse Events
measured Up to approximately 141 days
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed